In addition, FGF21 reduced the number of pro-fibrotic macrophages in the injured liver, potentially explaining why FGF21 counteracts all features of NASH, including hepatic steatosis, inflammation, and fibrogenesis. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.